AU2018211985B2 - Tissue-specific Wnt signal enhancing molecules and uses thereof - Google Patents

Tissue-specific Wnt signal enhancing molecules and uses thereof Download PDF

Info

Publication number
AU2018211985B2
AU2018211985B2 AU2018211985A AU2018211985A AU2018211985B2 AU 2018211985 B2 AU2018211985 B2 AU 2018211985B2 AU 2018211985 A AU2018211985 A AU 2018211985A AU 2018211985 A AU2018211985 A AU 2018211985A AU 2018211985 B2 AU2018211985 B2 AU 2018211985B2
Authority
AU
Australia
Prior art keywords
tissue
domain
molecule
wnt
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018211985A
Other languages
English (en)
Other versions
AU2018211985A1 (en
Inventor
Jennifer Jean BRADY
Yang Li
Aaron Ken Sato
Teppei YAMAGUCHI
Wen-Chen Yeh
Zhengjian ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Publication of AU2018211985A1 publication Critical patent/AU2018211985A1/en
Assigned to Surrozen Operating, Inc. reassignment Surrozen Operating, Inc. Amend patent request/document other than specification (104) Assignors: SURROZEN, INC.
Application granted granted Critical
Publication of AU2018211985B2 publication Critical patent/AU2018211985B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
AU2018211985A 2017-01-26 2018-01-26 Tissue-specific Wnt signal enhancing molecules and uses thereof Active AU2018211985B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762450804P 2017-01-26 2017-01-26
US62/450,804 2017-01-26
US201762487135P 2017-04-19 2017-04-19
US62/487,135 2017-04-19
PCT/US2018/015595 WO2018140821A1 (en) 2017-01-26 2018-01-26 Tissue-specific wnt signal enhancing molecules and uses thereof

Publications (2)

Publication Number Publication Date
AU2018211985A1 AU2018211985A1 (en) 2019-07-18
AU2018211985B2 true AU2018211985B2 (en) 2025-02-13

Family

ID=62978866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018211985A Active AU2018211985B2 (en) 2017-01-26 2018-01-26 Tissue-specific Wnt signal enhancing molecules and uses thereof

Country Status (7)

Country Link
US (2) US11958891B2 (enExample)
EP (1) EP3574019A4 (enExample)
JP (3) JP7305543B2 (enExample)
CN (1) CN110234662A (enExample)
AU (1) AU2018211985B2 (enExample)
CA (1) CA3050133A1 (enExample)
WO (1) WO2018140821A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CA3085596A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
US20220041753A1 (en) * 2018-12-27 2022-02-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for membrane clearance of target receptors
CN113544150A (zh) * 2019-02-11 2021-10-22 瑟罗泽恩公司 眼部病症中wnt信号传导的调节
WO2020206005A1 (en) * 2019-04-02 2020-10-08 Surrozen, Inc. Modulation of wnt signaling in auditory disorders
AU2020291208A1 (en) * 2019-06-11 2022-01-06 Antlera Therapeutics Inc. Multivalent FZD and Wnt binding molecules and uses thereof
EP3986912A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
WO2021142410A1 (en) * 2020-01-09 2021-07-15 Retinal Solutions, LLC Neural regeneration with synthetic protein administration
CN115427446A (zh) * 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
EP4244256A4 (en) * 2020-11-10 2024-12-25 The Scripps Research Institute ANTIBODIES FOR OPIOID TREATMENTS
JP2023549854A (ja) * 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
CN113293214A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用
WO2023285686A2 (en) * 2021-07-15 2023-01-19 Diogenx Recombinant variants of r-spondin proteins and their use
EP4428238A1 (en) * 2021-11-02 2024-09-11 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
CN116789843B (zh) * 2022-03-16 2024-09-17 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用
CN116836274B (zh) * 2022-03-23 2024-11-22 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
EP4543928A2 (en) * 2022-06-21 2025-04-30 Surrozen Operating, Inc. Modulation of wnt signalling in corneal disorders
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用
CN120647751B (zh) * 2025-08-18 2025-12-02 成都迈科康生物科技有限公司 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
EP2305274A1 (en) * 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
US20140044713A1 (en) * 2011-04-14 2014-02-13 Koninklijke Nederlandse Akademie Van Wetenschappen Compounds
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018132572A1 (en) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
KR101351208B1 (ko) 2006-06-21 2014-01-14 온코세라피 사이언스 가부시키가이샤 Ｆｚｄ10에 대한 종양-표적화 모노클로날 항체 및 이의 용도
EP3111955B1 (en) 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
JPWO2008093646A1 (ja) 2007-02-01 2010-05-20 国立大学法人 奈良先端科学技術大学院大学 Ｗｎｔシグナル伝達系活性化ペプチド
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
WO2010092457A1 (en) 2009-02-10 2010-08-19 Nokia Corporation Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
JP5989544B2 (ja) 2009-12-09 2016-09-07 バイエル・ファルマ・アクティエンゲゼルシャフト 抗Ｃ４．４ａ抗体およびその使用
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
JP2014511694A (ja) 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
RU2017120287A (ru) 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
MX2015001678A (es) 2012-08-09 2015-08-14 Roche Glycart Ag Anticuerpos asgpr y sus usos.
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
JP2017518040A (ja) * 2014-04-21 2017-07-06 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｒｎｆ４３抗体および使用方法
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｗｎｔシグナリングアゴニスト分子
SG11201703403TA (en) 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
HK1248539A1 (zh) 2015-04-17 2018-10-19 梅里麦克制药股份有限公司 借助塞里班土单抗的组合治疗
MX2018007061A (es) 2015-12-08 2018-08-15 Regeneron Pharma Composiciones y metodos para enzimas de internalizacion.
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
WO2018107116A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2020518584A (ja) 2017-05-02 2020-06-25 中外製薬株式会社 細胞傷害誘導治療剤
GB201708330D0 (en) 2017-05-24 2017-07-05 Koninklijke Nederlandse Akademie Van Wetenschappen Fusion protein for enhancing intestinal regeneration
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CA3085596A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
CN120623353A (zh) 2018-07-05 2025-09-12 瑟罗泽恩奥普瑞汀公司 多特异性wnt替代分子和其用途
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
US20220064337A1 (en) 2018-12-19 2022-03-03 Surrozen, Inc. Antigen binding formats for receptor complexes
CN113544150A (zh) 2019-02-11 2021-10-22 瑟罗泽恩公司 眼部病症中wnt信号传导的调节
EP3938036A4 (en) 2019-03-11 2023-06-28 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders
WO2020206005A1 (en) 2019-04-02 2020-10-08 Surrozen, Inc. Modulation of wnt signaling in auditory disorders
AU2020291208A1 (en) 2019-06-11 2022-01-06 Antlera Therapeutics Inc. Multivalent FZD and Wnt binding molecules and uses thereof
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
CN115427446A (zh) 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
WO2022192445A1 (en) 2021-03-10 2022-09-15 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
EP2305274A1 (en) * 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
US20140044713A1 (en) * 2011-04-14 2014-02-13 Koninklijke Nederlandse Akademie Van Wetenschappen Compounds
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018132572A1 (en) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules

Also Published As

Publication number Publication date
JP7305543B2 (ja) 2023-07-10
JP2023078467A (ja) 2023-06-06
AU2018211985A1 (en) 2019-07-18
EP3574019A1 (en) 2019-12-04
US20240279303A1 (en) 2024-08-22
CA3050133A1 (en) 2018-08-02
EP3574019A4 (en) 2021-03-03
JP2025020347A (ja) 2025-02-12
JP7635291B2 (ja) 2025-02-25
CN110234662A (zh) 2019-09-13
JP2020506701A (ja) 2020-03-05
WO2018140821A1 (en) 2018-08-02
US20200048324A1 (en) 2020-02-13
US11958891B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
AU2018211985B2 (en) Tissue-specific Wnt signal enhancing molecules and uses thereof
JP7657249B2 (ja) 治療用ヌクレアーゼ組成物および方法
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
CN110719920B (zh) 蛋白质异二聚体及其用途
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
AU2016329120B2 (en) Bispecific antibodies specific for a costimulatory TNF receptor
KR102648966B1 (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
CN109311973A (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
HK1259474A1 (zh) 新的免疫缀合物
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
KR20160032041A (ko) 단백질 약물의 불활성화를 위한 항체 로커
CN116322776A (zh) 用于病毒治疗剂中的多向生物转运的材料和方法
KR20230165829A (ko) 이중특이적 분자 및 관련 조성물 및 방법
RU2840013C1 (ru) Способ получения конъюгата антитело-лекарственное средство на основе эрибулина

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SURROZEN OPERATING, INC.

Free format text: FORMER NAME(S): SURROZEN, INC.

FGA Letters patent sealed or granted (standard patent)